Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of Dabigatran Etexilate 150 mg capsules vs PRADAXA 150 mg in healthy Thai volunteers under fasting conditions
TCTR20240916009Phase 1Unknown
- Sponsor
- Bio-innova
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dabigatran (2 arms), sponsored by Bio-innova. Primary endpoint: Bioequivalence of Dabigatran Etexilate 150 mg vs PRADAXA 150 mg. Status: unknown.
02
Drugs
dabigatran
Beyond the preview
Go deeper on TCTR20240916009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240916009.